PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
PHXM was delisted on the 8th of March, 2024.
3 hedge funds and large institutions have $3.59K invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 6 closing their positions.
63% less funds holding
Funds holding: 8 → 3 (-5)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
96% less capital invested
Capital invested by funds: $85.7K → $3.59K (-$82.1K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$39 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPIM
Vanguard Personalized Indexing Management
Oakland,
California
|
-$18.7K |
| 2 |
Mariner
Overland Park,
Kansas
|
-$18.4K |
| 3 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
-$14.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$12.1K |
| 5 |
Millennium Management
New York
|
-$8.81K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ADL
1
Asset Dedication LLC
San Francisco,
California
| $2K | – | – | – |
|
|
IC
2
Ikarian Capital
Dallas,
Texas
| $1.56K | -$6 | -1 | -0.3% |
|
|
3
UBS Group
Zurich,
Switzerland
| $36 | +$39 | +7 | New |
|
|
VPIM
4
Vanguard Personalized Indexing Management
Oakland,
California
| – | -$18.7K | -2,427 | Closed |
|
|
BBA
5
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| – | -$14.7K | -2,400 | Closed |
|
|
6
Mariner
Overland Park,
Kansas
| – | -$18.4K | -2,390 | Closed |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$12.1K | -1,661 | Closed |
|
|
8
Millennium Management
New York
| – | -$8.81K | -1,207 | Closed |
|
9
Group One Trading
Chicago,
Illinois
| – | -$7.73K | -1,059 | Closed |
|
PHXM Hedge Fund Activity: Q3 2023 in Review
3 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q3 2023, worth a combined $3.59K — down 96% from $85.7K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PHXM and 1 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $39. The largest seller was Vanguard Personalized Indexing Management, exiting entirely with an estimated $18.7K sold.
- 3 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q3 2023, down from 8 in Q2 2023.
- Funds reported $3.59K of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q3 2023, down 96% quarter-over-quarter.
- 1 fund opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q3 2023 and 6 closed out, a net change of -5 holders.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares buyer in Q3 2023 was UBS Group, an estimated $39 added.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares seller in Q3 2023 was Vanguard Personalized Indexing Management, an estimated $18.7K sold.
Based on aggregated 13F filings for Q3 2023.